We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

134 hedge funds and large institutions have $1B invested in Epizyme, Inc in 2019 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 53 increasing their positions, 27 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 27

80% more funds holding in top 10

Funds holding in top 10: 59 (+4)

68% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 22

11% more funds holding

Funds holding: 121134 (+13)

4% more capital invested

Capital invested by funds: $965M → $1B (+$38M)

67% less call options, than puts

Call options by funds: $687K | Put options by funds: $2.1M

Holders
134
Holders Change
+13
Holders Change %
+10.74%
% of All Funds
2.91%
Holding in Top 10
9
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+80%
% of All Funds
0.2%
New
37
Increased
53
Reduced
27
Closed
22
Calls
$687K
Puts
$2.1M
Net Calls
-$1.42M
Net Calls Change
-$369K
Name Holding Trade Value Shares
Change
Change in
Stake
Primecap Management
1
Primecap Management
California
$129M +$30.9K +2,400 +0%
RG
2
Redmile Group
California
$110M +$13.3M +1,035,122 +13%
Vanguard Group
3
Vanguard Group
Pennsylvania
$88.8M +$21M +1,630,171 +30%
PAI
4
Palo Alto Investors
California
$87M
BlackRock
5
BlackRock
New York
$80.8M +$20M +1,552,216 +32%
CCM
6
Consonance Capital Management
New York
$59.7M +$16.5M +1,281,798 +37%
NMC
7
NEA Management Company
Maryland
$54.9M -$32.2M -2,500,000 -36%
Fidelity Investments
8
Fidelity Investments
Massachusetts
$40.2M -$3.59M -278,724 -8%
State Street
9
State Street
Massachusetts
$38.6M +$10.1M +786,890 +34%
RSCM
10
Rock Springs Capital Management
Maryland
$23.2M +$1.24M +96,725 +6%
Victory Capital Management
11
Victory Capital Management
Texas
$21.1M +$558K +43,360 +3%
AG
12
Artal Group
Luxembourg
$20.7M -$1.29M -100,000 -6%
FCMI
13
Foresite Capital Management II
California
$18.7M
OM
14
Opaleye Management
Massachusetts
$17.1M
FCMI
15
Foresite Capital Management III
California
$12.5M
Geode Capital Management
16
Geode Capital Management
Massachusetts
$12M +$1.77M +137,717 +17%
Norges Bank
17
Norges Bank
Norway
$11.1M -$3.15M -245,077 -22%
Northern Trust
18
Northern Trust
Illinois
$9.99M +$692K +53,806 +7%
Millennium Management
19
Millennium Management
New York
$9.61M -$13M -1,008,391 -57%
Point72 Asset Management
20
Point72 Asset Management
Connecticut
$9.24M -$4.75M -368,812 -33%
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$8.86M +$1.95M +151,746 +27%
T. Rowe Price Associates
22
T. Rowe Price Associates
Maryland
$7.98M +$2.97M +231,109 +57%
JP Morgan Chase
23
JP Morgan Chase
New York
$6.45M +$1.02M +79,251 +18%
RPAM
24
Rhenman & Partners Asset Management
Sweden
$6.2M +$5.59M +434,474 +734%
Goldman Sachs
25
Goldman Sachs
New York
$5.9M +$748K +58,153 +14%

EPZM Hedge Fund Activity: Q2 2019 in Review

134 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q2 2019, worth a combined $1B — up 3.9% from $965M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new EPZM positions and 22 closed out — a net gain of 15 holders — while 53 added to existing stakes and 27 trimmed.

The largest buyer was Vanguard Group, adding an estimated $21M. The largest seller was NEA Management Company, cutting an estimated $32.2M.

  • 134 institutional investors held Epizyme, Inc (EPZM) as of Q2 2019, up from 121 in Q1 2019.
  • Funds reported $1B of Epizyme, Inc stock for Q2 2019, up 3.9% quarter-over-quarter.
  • 37 funds opened new Epizyme, Inc positions in Q2 2019 and 22 closed out, a net change of +15 holders.
  • The largest Epizyme, Inc buyer in Q2 2019 was Vanguard Group, an estimated $21M added.
  • The largest Epizyme, Inc seller in Q2 2019 was NEA Management Company, an estimated $32.2M sold.

Based on aggregated 13F filings for Q2 2019.